WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

“Cogent is preparing to report data from three bezuclastinib pivotal clinical trials this year,” said Andrew Robbins, the company’s President and Chief Executive Officer. “Given our strong ...